Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC3944 | A 205804 |
| Selective inhibitor of E-selectin and ICAM-1 expression (IC50 values are 20, 25 and > 1000 nM for TNF-α-induced E-selectin, ICAM-1 and VCAM-1 expression respectively). Effective inhibitor of cell-cell adhesion in an in vitro flow experiment. | |
| BCC3945 | BIO 1211 |
| Selective, high affinity α4β1 (Very Late Antigen 4; VLA-4) inhibitor; displays 200-fold selectivity for the activated form of α4β1 (KD = 70 pM; IC50 = 0.004 μM). Selective for α4β1 over a range of other integrins (IC50 >100 μM for α1β1, α5β1 and α6β1). | |
| BCC3947 | SLIGRL-NH2 |
| Agonist peptide derived from the N-terminus of protease-activated receptor-2 (PAR2). Activates PAR2 (EC50 ~ 5 μM) and facilitates gastrointestinal transit in mice in vivo. Control peptide LRGILS-NH2 also available. | |
| BCC3948 | TFLLR-NH2 |
| Peptide derived from the protease-activated receptor-1 (PAR1) that acts as a PAR1 selective agonist (EC50 = 1.9 μM). Stimulates PAR1-mediated plasma extravasation in vivo. Control Peptide RLLFT-NH2 also available. | |
| BCC3949 | AY-NH2 |
| Selective PAR4 receptor agonist peptide. Stimulates platelet aggregation in vitro (EC50 = 15 μM). Exhibits an increase in paw thickness in the paw edema inflammation model in vivo. | |
| BCC3950 | Thrombin Receptor Agonist Peptide |
| Agonist at the thrombin receptor; causes platelet aggregation (EC50 = 4 μM) and secretion. | |
| BCC3957 | TRAP-6 |
| Peptide fragment (residues 42-47) of protease-activated receptor 1 (PAR1) that acts as a PAR1 agonist. Stimulates platelet aggregation (EC50 = 0.8 μM), promotes intracellular Ca2+ mobilization and induces rapid phosphodiesterase 3A (PDE3A) phosphorylation in vitro. | |
| BCC3959 | SLIGKV-NH2 |
| Protease-activated receptor 2 (PAR2) agonist (Ki = 9.64 μM and IC50 = 10.4 μM). Corresponds to the tethered ligand exposed by trypsin cleavage of PAR-2. Control peptide VKGILS-NH2 also available. | |
